Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial

• Published in: Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2022-05, Vol.32 (5), p.1288-1291
• Main Authors: Noto, Davide, Petta, Salvatore, Giammanco, Antonina, Spina, Rossella, Cabibbi, Daniela, Porcasi, Rossana, Caldarella, Rosalia, Ciaccio, Marcello, Muratore, Roberto, Cefalù, Angelo B., Craxi, Antonio, Averna, Maurizio
• Format: Article
• Language: English
• Subjects: Biopsy - adverse effects; Double-Blind Method; Ezetimibe; Ezetimibe - adverse effects; Humans; Life Style; Liver biopsy; Non-alcoholic Fatty Liver Disease - diagnosis; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic steatohepatitis; Randomized controlled trial; Treatment Outcome
• ISSN: 0939-4753; 1590-3729
• DOI: 10.1016/j.numecd.2022.01.024

The LISTEN trial (ClinicalTrial.gov accession: NCT01950884) is a phase IV 52 weeks double blind parallel randomized controlled trial that evaluated the effect of ezetimibe plus lifestyle and dietary intervention (eze) vs. lifestyle and dietary intervention alone (placebo) on progression and complications of non-alcoholic steatohepatitis (NASH) evaluated by liver histology. Forty patients with NASH ascertained by histology were randomly allocated on the two study groups and subjected to a follow-up of 52 weeks, when they underwent a second liver biopsy. Main composite end point (EP) was based on the histological improvement in the severity of NASH. Thirty patients completed the study, Eze treatment was not able to improve the primary EP in comparison with placebo, with and odds ratio of 1.029 (0.18–6.38), p = 0.974. Treatment emergent adverse events registered during the study were not more prevalent in the treatment arm. ezetimibe administered on top of lifestyle and dietary modification failed to improve the histology of NASH in comparison with lifestyle and dietary modification alone. ClinicalTrial.gov: NCT01950884. •Ezetimibe is lipid lowering drug able to promote cholesterol efflux from the liver.•Ezetimibe has been proposed to treat NAFLD.•Ezetimibe use in NAFLD has been tested in a randomized controlled trial.•Ezetimibe failed to improve NAFLD features measured by liver biopsies.•Diet and Lifestyle remain the main therapeutic options for NAFLD.